Navigation Links
Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million
Date:10/13/2011

CRANBURY, N.J., Oct. 13, 2011 /PRNewswire/ -- Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to confidentiality terms in the agreement. The combined value of the agreements to Oncobiologics totals close to $80 million.

Dennis O'Donnell, CEO of Parilis Biopharmaceuticals said, "We are very excited about this agreement with Oncobiologics.  This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics' capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success."

Oncobiologics Vice President of Business Development, Jeremy Caudill commented, "These programs represent a significant milestone for Oncobiologics. They are a validation of our dual strategies; as a fully integrated Biopharmaceutical company, as well as providing world-class proof-of-concept services to customers and partners."

Caudill added, "These agreements also recognize the strength and depth of the team assembled here at Oncobiologics. For a major pharmaceutical organization to entrust an important technical program of this scope reflects the confidence they have in our capabilities.  Likewise, Dennis O'Donnell brings a track-record of successes and has chosen Oncobiologics largely on the strength of our team."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development all the way through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
2. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
3. ULURU Inc. Announces Altrazeal® Agreement for the European Market
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Health Industry Group Purchasing Association Announces Name Change to Healthcare Supply Chain Association (HSCA) to Reflect Expertise, Experience and Position Within Healthcare Supply Chain
6. I-Flow LLC, a Kimberly-Clark Health Care Company Announces Agreement for ON-Q® Products With HealthTrust Purchasing Group
7. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Third Quarter Ended September 30, 2011
8. Webcast Alert: Heska Announces Third Quarter 2011 Earnings Conference Call Webcast
9. Lilly Announces Changes in Senior Management
10. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
11. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Film Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ... position, rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
Breaking Medicine News(10 mins):